Published in Clin Cancer Res on December 15, 2005
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther (2013) 1.80
Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol (2008) 1.13
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer (2011) 1.08
Mitochondrial regulation of epigenetics and its role in human diseases. Epigenetics (2012) 0.98
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol (2007) 0.97
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol (2014) 0.91
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther (2014) 0.89
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J (2012) 0.86
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res (2006) 0.84
Epigenetic regulatory mechanisms associated with infertility. Obstet Gynecol Int (2010) 0.83
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Br J Clin Pharmacol (2008) 0.82
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer (2010) 0.81
DNA methylotype analysis in colorectal cancer. Oncol Rep (2008) 0.80
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J (2010) 0.80
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res (2008) 0.79
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. Int J Mol Sci (2015) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers. Br J Cancer (2013) 0.76
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Semin Colon Rectal Surg (2008) 0.75
Frequent intragenic rearrangements of DPYD in colorectal tumours. Pharmacogenomics J (2014) 0.75
Casticin inhibits the activity of transcription factor Sp1 and the methylation of RECK in MGC803 gastric cancer cells. Exp Ther Med (2016) 0.75
Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups. J Korean Med Sci (2013) 0.75
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep (2016) 0.75
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs (2009) 1.99
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 1.78
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem (2002) 1.54
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res (2002) 1.35
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res (2013) 1.24
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol (2005) 1.23
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol (2011) 1.11
Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol (2008) 1.08
The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc (2010) 1.08
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res (2005) 1.04
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J (2007) 1.04
DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol (2006) 1.02
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics (2002) 1.01
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res (2006) 1.00
Peripheral neuropathy associated with capecitabine. Anticancer Drugs (2004) 0.99
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res (2004) 0.99
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res (2014) 0.98
MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol (2013) 0.98
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol (2006) 0.94
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol (2002) 0.92
The clinical case for proton beam therapy. Radiat Oncol (2012) 0.90
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther (2007) 0.89
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther (2014) 0.89
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics (2007) 0.88
Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet (2012) 0.88
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res (2010) 0.87
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem (2002) 0.87
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics (2008) 0.86
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther (2002) 0.85
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pak J Med Sci (2007) 0.85
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res (2006) 0.84
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. J Clin Oncol (2014) 0.83
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol (2007) 0.83
Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer (2005) 0.83
The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta (2006) 0.82
A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics (2002) 0.82
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf (2009) 0.81
Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics (2005) 0.81
HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer (2013) 0.81
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Mol Carcinog (2005) 0.80
Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol (2008) 0.80
Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol (2006) 0.80
Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change? N Engl J Med (2004) 0.80
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anticancer Drugs (2006) 0.80
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics (2007) 0.79
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics (2016) 0.79
An evolving role for oral fluoropyrimidine drugs. J Clin Oncol (2002) 0.79
Perspectives in the treatment of colorectal cancer. Semin Oncol (2004) 0.78
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (2012) 0.77
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs (2010) 0.76
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? JOP (2008) 0.76
(13)C-5-FU breath test current status and future directions: a comprehensive review. J Breath Res (2009) 0.76
Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma. Clin Cancer Res (2003) 0.75
ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer? Clin Cancer Res (2010) 0.75
Hypokalemia secondary to capecitabine: a hidden toxicity? Ther Clin Risk Manag (2007) 0.75
Genetic testing in cancer therapeutics. Clin Cancer Res (2006) 0.75
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemother Pharmacol (2003) 0.75
Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem (2002) 0.75